On treatment prediction of post-treatment sustained response to Peginterferon alfa-2a for HBeAg-negative Chronic Hepatitis B (CHB) patients using HBsAg and HBV DNA levels at weeks 12 and 24: PERSEAS cohort final results

被引：0

作者：

Goulis, Ioannis ^{[1
]}

Karatapanis, Stylianos ^{[2
]}

Akriviadis, Evangelos A. ^{[1
]}

Deutsch, Melanie ^{[3
]}

Dalekos, George N. ^{[4
,5
]}

Raptopoulou-Gigi, Maria ^{[3
]}

Mimidis, Konstantinos ^{[6
]}

Germanidis, Georgios ^{[7
]}

Triantos, Christos K. ^{[8
]}

Drakoulis, Christos ^{[9
]}

Chounta, Athina ^{[10
]}

Vafiadis, Irene ^{[11
]}

Hatzis, Grigorios ^{[12
]}

Gagalis, Asterios ^{[13
]}

Vlachogiannakos, Jiannis ^{[11
]}

Zintzaras, Elias ^{[14
,15
]}

Koulouris, Sokratis ^{[16
]}

Bakalos, George ^{[14
,16
]}

Papatheodoridis, George V. ^{[3
]}

机构：

[1] Hippokrateion Hosp, Dept Internal Med 4, Thessaloniki, Greece

[2] Rhodes Hosp, Dept Internal Med 1, Rhodes, Greece

[3] Hippokrateion Hosp, Dept Internal Med 2, Athens, Greece

[4] Univ Thessaly, Sch Med, Dept Med, Larisa, Greece

[5] Univ Thessaly, Res Lab Internal Med, Larisa, Greece

[6] Democritus Univ Thrace, Sch Med, Dept Internal Med 1, Alexandroupolis, Greece

[7] AHEPA Hosp, Dept Gastroenterol, Internal Med Clin 1, Thessaloniki, Greece

[8] Univ Patras, Sch Med, Dept Gastroenterol, Patras, Greece

[9] Nikaia Hosp, Dept Internal Med 2, Athens, Greece

[10] Univ Hosp ATTIKON, Dept Internal Med, Athens, Greece

[11] Laiko Univ, Gen Hosp, Dept Internal Med Propaedeut, Athens, Greece

[12] Laikon Gen Hosp, Physiopathol Dept, Athens, Greece

[13] Papageorgiou Gen Hosp, Dept Gastroenterol, Thessaloniki, Greece

[14] Univ Thessaly, Sch Med, Dept Biomath, Larisa, Greece

[15] Tufts Univ, Sch Med, Tufts Med Ctr, Inst Clin Res & Hlth Policy Studies, Boston, MA 02111 USA

[16] Roche Hellas, Med Affairs, Athens, Greece

来源：

HEPATOLOGY | 2013年 / 58卷

关键词：

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

1015

引用

页码：697A / 698A

页数：2

共 50 条

[31] INTRAHEPATIC HBSAG PREDICTS TREATMENT RESPONSE IN HBEAG NEGATIVE CHRONIC HEPATITIS B PATIENTS TREATED WITH PEGINTERFERON ALFA-2A AND ADEFOVIR: AN INTERIM ANALYSIS
Takkenberg, Bart
Terpstra, Valeska
Zaaijer, Hans L.
Weegink, Christine J.
Dijkgraaf, Marcel
Jansen, Peter L.
Beld, Marcel
Reesink, Hendrik W.
HEPATOLOGY, 2010, 52 (04) : 988A - 988A
[32] BASELINE HBSAG LEVEL AND ON-TREATMENT HBSAG AND HBV DNA DECLINE PREDICT SUSTAINED VIROLOGICAL RESPONSE IN HBEAG NEGATIVE CHRONIC HEPATITIS B PATIENTS TREATED WITH PEGINTERFERON ALFA-2A (PEGASYS®) AND ADEFOVIR (HEPSERA); AN INTERIM ANALYSIS
Takkenberg, Bart
Zaaijer, Hans L.
de Niet, Annikki
Weegink, Christine J.
Terpstra, Valeska
Koot, Maarten
Dijkgraaf, Marcel
Jansen, Peter L.
Janssen, Harry L.
Beld, Marcel
Reesink, Hendrik W.
HEPATOLOGY, 2009, 50 (04) : 538A - 539A
[33] Response to peginterferon alfa-2a (40KD) (PEGASYS) treatment in patients with bridging fibrosis in HBeAg-positive and HBeAg-negative chronic hepatitis B
Cooksley, Graham
Lau, George
Marcellin, Patrick
Piratvisuth, Teerha
Lai, Ming-Yang
Bonino, Ferruccio
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2006, 21 : A32 - A32
[34] SAFETY AND TOLERABILITY OF EXTENDED (96 WEEKS) TREATMENT WITH PEGINTERFERON ALFA-2A [40KD] IN GENOTYPE D PATIENTS WITH HBEAG-NEGATIVE CHRONIC HEPATITIS B
Lampertico, Pietro
Vigano, Mauro
Di Costanzo, Giovan Giuseppe
Sagnelli, Evangelista
Fasano, Massimo
Di Marco, Vito
Boninsegna, Sara
Farci, Patrizia
Fargion, Silvia
Giuberti, Tiziana
Iannacone, Claudio
Massetto, Benedetta
Martins, Eduardo B.
Colombo, Massimo
HEPATOLOGY, 2010, 52 (04) : 387A - 387A
[35] Significant reduction of HBsAg in the sera of HBeAg-negative chronic hepatitis B patients treated with peginterferon alfa-2A alone or in combination with lamivudine
Brunetto, Maurizia
Bonino, Ferruccio
Moriconi, Francesco
Patrick, Marcellin
George, Lau K.
Patrizia, Farci
Yurdaydin, Cihan
Piratvisuth, Teerha
Luo, Kangxian
Wang, Yuming
Hadziyannis, Stephanos
Wolf, Eva
Matei, Popescu
HEPATOLOGY, 2006, 44 (04) : 549A - 549A
[36] PREDICTION OF SUSTAINED RESPONSE TO PEGINTERFERON ALFA-2B FOR HBEAG-POSITIVE CHRONIC HEPATITIS B USING ON-TREATMENT HBSAG DECLINE
Sonneveld, Milan J.
Rijckborst, Vincent
Boucher, Charles A.
Hansen, Bettina E.
Janssen, Harry L.
HEPATOLOGY, 2010, 52 (04) : 530A - 530A
[37] ADD-ON PEGINTERFERON ALFA-2A SIGNIFICANTLY REDUCES HBSAG LEVELS IN HBEAG-NEGATIVE, GENOTYPE D CHRONIC HEPATITIS B PATIENTS FULLY SUPPRESSED ON NUCLEOT(S)IDE ANALOGUES TREATMENT: FINAL RESULTS OF THE HERMES STUDY
Lampertico, P.
Brunetto, M. R.
Craxi, A.
Gaeta, G. B.
Rizzetto, M.
Rozzi, A.
Colombo, M.
JOURNAL OF HEPATOLOGY, 2016, 64 : S223 - S223
[38] Early reduction of serum HBsAg Levels in HBeAg-negative chronic hepatitis B patients achieving sustained virological response after peginterferon α-2a± ribavirin treatment
Rijckborst, V.
ter Borg, M. J.
Akarca, U. S.
Grima, P.
Flisiak, R.
Zouboulis, I. Vafiadis
Tripi, S.
van Doornum, G. J. J.
Verhey, E.
van Vuuren, A. J.
Hansen, B. E.
Janssen, H. L. A.
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2009, 21 (03) : A65 - A65
[39] INCREASING RATES OF HBsAg CLEARANCE AND SEROCONVERSION IN PATIENTS WITH HBeAg-NEGATIVE DISEASE TREATED WITH PEGINTERFERON ALFA-2A ± LAMIVUDINE: RESULTS OF 5-YEAR POST-TREATMENT FOLLOW UP
Marcellin, P.
Piratvisuth, T.
Brunetto, M.
Bonino, F.
Lau, G. K. K.
Farci, P.
Yurdaydin, C.
Gurel, S.
Wu, J.
Popescu, M.
JOURNAL OF HEPATOLOGY, 2009, 50 : S336 - S336
[40] On-treatment HBsAg decline in HBeAg-negative patients as a predictor of response to peginterferon alfa-2a (40kd) therapy 3 years post-treatment: Potential for response-guided therapy
Brunetto, M.
Bonino, E.
Lau, G. K. K.
Farci, R.
Yurdaydin, C.
Piratvisuth, T.
Hadziyannis, S.
Lu, Z. -M.
Wu, J.
Popescu, M.
Marcellin, P.
JOURNAL OF HEPATOLOGY, 2008, 48 : S254 - S254

← 1 2 3 4 5 →